Selank vs Semax

Selank and Semax are the two most significant outputs of Russian peptide neuroscience. They share an origin story: both were developed at the Institute of Molecular Genetics of the Russian Academy of Sciences in Moscow, both use an identical C-terminal Pro-Gly-Pro stabilizing tripeptide, and both are administered intranasally to exploit the olfactory pathway's direct access to the brain. Despite these structural and institutional similarities, they produce fundamentally different effects through entirely different mechanisms. Selank, derived from the immune peptide tuftsin, is Russia's clinical answer to benzodiazepines — an anxiolytic that calms without sedating and modulates the immune system in parallel. Semax, derived from the ACTH(4-7) fragment, is a cognitive accelerator that upregulates BDNF, sensitizes dopaminergic neurons, and has clinical approval for stroke recovery.

Understanding where these two peptides differ is the starting point for using either of them well, and for understanding why their combination has become one of the most established nootropic stacks in the research community.

Selank: Strengths and Best Uses

Selank (TP-7) was engineered to solve a specific problem: tuftsin, the naturally occurring immune tetrapeptide it is derived from, had a plasma half-life measured in seconds due to rapid enzymatic degradation. By appending the stabilizing tripeptide Pro-Gly-Pro to tuftsin's C-terminus, Myasoedov's team created a heptapeptide that retains tuftsin's immunomodulatory properties while gaining pronounced neurotropic effects and resistance to enzymatic degradation long enough for clinical utility.

GABAergic Modulation Without Sedation

The most clinically significant mechanism of Selank is its allosteric modulation of GABA-A receptors. Unlike benzodiazepines, which bind directly to the benzodiazepine site on the GABA-A receptor and produce potent but sedating anxiolysis, Selank appears to modulate GABAergic neurotransmission indirectly. It alters the expression of genes encoding GABA-A receptor subunits and GABA transporters without the full receptor occupancy that produces sedation, muscle relaxation, and dependence.

The clinical consequence is striking: in a head-to-head comparison with phenazepam (a potent benzodiazepine widely prescribed in Russia), Selank achieved comparable anxiety reduction scores without the sedation, muscle relaxation, tolerance development, or withdrawal syndrome that define the benzodiazepine class. A second comparison with medazepam yielded similar results, with Selank additionally demonstrating antiasthenic and psychostimulant properties absent in the benzodiazepine group.

Enkephalin Stabilization

Selank also inhibits enzymes that degrade endogenous enkephalins, the body's own opioid peptides involved in mood regulation, stress buffering, and pain modulation. In patients with generalized anxiety disorder, leu-enkephalin levels are measurably reduced, and the deficit correlates with disease severity. Selank treatment in the medazepam comparison trial produced measurable increases in leu-enkephalin levels that correlated with anxiety score improvements — a neurochemical change absent in the benzodiazepine group. This mechanism addresses an underlying neurochemical deficit rather than simply suppressing anxiety symptoms through receptor occupation.

BDNF Upregulation and Neuroplasticity

Selank upregulates BDNF mRNA expression in the hippocampus, particularly under stress conditions where glucocorticoids would normally suppress it. This BDNF-mediated neuroplastic effect develops over days to weeks of treatment and provides the mechanistic basis for the cognitive improvements — improved memory consolidation, enhanced verbal fluency, greater cognitive flexibility under pressure — that distinguish Selank from conventional anxiolytics that impair cognition rather than preserve it.

Immunomodulation: A Unique Dimension

Selank retains tuftsin's immunomodulatory properties and extends them. Research examining 84 inflammation-related genes found that Selank significantly altered the expression of 34, including selective interferon-alpha induction without broad inflammatory activation, modulation of IL-6, and enhancement of phagocytic activity consistent with its tuftsin heritage. This immune dimension is pharmacologically unique among anxiolytics — virtually no conventional anxiety treatment has concurrent immune-enhancing properties.

Where Selank Excels

Selank is the right peptide when anxiety is the primary target, when anxiolytic properties need to coexist with preserved or enhanced cognition, when immune support alongside neurological effects is desired, and when the goal is calm but engaged mental performance rather than stimulated output. It is also the better choice for evening administration, as it does not interfere with sleep architecture.

Semax: Strengths and Best Uses

Semax was created in 1982 by Myasoedov and Ashmarin at the same Institute of Molecular Genetics, building on decades of research into ACTH fragments with nootropic activity. The ACTH(4-7) sequence had been shown to possess potent neurotrophic effects independent of adrenocortical activity, but was impractical therapeutically due to rapid degradation. The addition of Pro-Gly-Pro extended biological half-life while contributing independent anti-inflammatory properties. The result was a compound formally approved in Russia in two formulations — 0.1% for cognitive enhancement and general neuroprotection, 1% for acute neurological conditions including stroke — and added to the Russian List of Vital and Essential Drugs in December 2011.

BDNF and NGF Upregulation: The Core Mechanism

Semax's most extensively documented effect is its potent upregulation of brain-derived neurotrophic factor and nerve growth factor. Intranasal administration increases BDNF mRNA in the rat hippocampus and frontal cortex within 30 to 90 minutes, through CREB pathway activation. Phosphorylated CREB drives neurotrophin gene expression; elevated BDNF activates the TrkB receptor and downstream MAPK/ERK, PI3K/Akt, and PLCgamma cascades. These cascades strengthen synapses, promote dendritic branching, support neurogenesis, and underlie long-term potentiation — the cellular machinery of learning and memory.

Critically, Semax upregulates BDNF more potently and through a more direct transcriptional mechanism than Selank. Where Selank's BDNF effect is primarily observed under stress conditions (counteracting cortisol-mediated suppression), Semax drives active BDNF upregulation regardless of stress state. This distinction matters: Semax is the superior choice when the goal is proactive cognitive enhancement rather than stress-protective preservation.

Dopaminergic and Serotonergic Sensitization

Semax modulates both dopaminergic and serotonergic systems in a pharmacologically distinctive way. In vivo microdialysis studies showed that Semax alone did not substantially alter basal dopamine concentrations, but dramatically enhanced the dopamine response to d-amphetamine administration — a sensitization effect suggesting Semax primes dopaminergic neurons rather than flooding synapses. Serotonin metabolite levels gradually increased to approximately 180% of baseline over one to four hours post-administration.

Neuroprotection at the Genomic Level

In cerebral ischemia-reperfusion models, Semax produced genome-wide transcriptional changes suppressing pro-inflammatory gene expression (Il1a, Il1b, Il6, Ccl3, Cxcl2) while activating neurotransmission-related genes. At the protein level, Semax modulated CREB, MMP-9 (a key mediator of blood-brain barrier breakdown post-ischemia), and JNK (a mediator of apoptotic cell death). The clinical translation of these mechanisms is supported by human trial data in stroke patients, where Semax administration increased plasma BDNF levels throughout the study period and accelerated functional recovery.

Where Semax Excels

Semax is the right peptide when cognitive enhancement is the primary goal, when neuroprotection is needed acutely, when the objective is proactive neuroplasticity rather than stress buffering, and when the desired subjective profile is mental sharpness and increased output capacity. It is strongly preferred for morning administration, and later afternoon or evening dosing should be avoided due to its dopaminergic stimulation interfering with sleep.

Head-to-Head: Mechanism Comparison

The mechanistic divergence between Selank and Semax is best understood by examining what each peptide actually changes at the molecular level.

The GABA vs. BDNF Distinction

Selank's fastest-acting mechanism is GABAergic modulation — producing anxiolysis within minutes of intranasal administration through changes in inhibitory neurotransmission. Semax has no meaningful GABAergic activity. Semax's fastest-acting mechanism is the rapid increase in BDNF transcription and dopaminergic sensitization, producing cognitive stimulation within 15 to 30 minutes. These are genuinely different starting points: one begins with inhibition (calming), the other with activation (stimulating).

Shared Neurotrophin Biology, Different Magnitude

Both peptides influence BDNF, but through different mechanisms and to different degrees. Semax drives direct, potent, CREB-mediated BDNF and NGF gene expression regardless of background stress levels. Selank upregulates BDNF primarily by counteracting stress-mediated suppression in the hippocampus. In a low-stress context, Semax will produce greater BDNF elevation. Under chronic stress conditions, both peptides contribute meaningful neuroplastic support, though through different routes.

Immune System: Selank's Exclusive Territory

No meaningful immune modulation has been documented for Semax at standard nootropic doses, though it does have anti-inflammatory effects in ischemic contexts through cytokine suppression. Selank, by contrast, consistently demonstrates immune modulation across multiple gene expression studies, reflecting its tuftsin heritage. For individuals seeking cognitive support alongside immune enhancement, Selank has a dimension Semax does not replicate.

The Dopamine Question

Semax's dopaminergic sensitization is clinically significant. It explains the subjective profile of sharper motivation and enhanced drive, and also explains the occasional transient anxiety some users experience at higher doses. Selank has no meaningful dopaminergic activity and does not produce these dopamine-related effects — including the occasional overstimulation. For users who are sensitive to dopaminergic compounds, or who experience anxiety on stimulants, Selank avoids this dimension entirely.

Timelines and Duration

Both peptides produce some effects within minutes of intranasal administration through direct neurotransmitter modulation. Both also produce longer-term effects through neuroplastic changes that develop over days to weeks. Selank's clinical protocol of 14-day courses reflects Russian approval parameters for its anxiolytic indication. Semax's clinical protocol of 10 to 30 day courses reflects its range of approved indications from cognitive enhancement to acute stroke treatment. For both peptides, the acute effects (minutes) and the neuroplastic effects (weeks) represent distinct temporal layers of the same compound's activity.

Safety Comparison

Selank Safety Profile

Selank has a remarkably clean safety profile across its clinical evidence base. The most commonly reported adverse effects are mild nasal irritation, transient stinging, and nasal dryness with repeated intranasal use. No serious adverse events have been documented in published clinical studies. Critically, Selank does not produce the sedation, cognitive impairment, tolerance, physical dependence, or withdrawal syndromes that make long-term benzodiazepine use problematic. The FDA's general immunogenicity concern applies theoretically to any compounded peptide but has produced no documented cases specifically linked to Selank.

Semax Safety Profile

Semax is similarly well-tolerated in its evidence base. The most commonly reported effects are nasal irritation, occasional headache, and sleep disturbance when administered too late in the day. Less common reports include transient anxiety or restlessness (more likely at higher doses due to dopaminergic activity), nausea, and mild blood pressure fluctuations. No serious adverse events have been reported in published research. The drug interaction consideration is more significant for Semax than for Selank: given its dopaminergic and serotonergic activity, combining Semax with SSRIs, MAOIs, antipsychotics, or stimulants warrants caution and ideally medical oversight.

Shared Risk Considerations

Both peptides are obtained through unregulated research chemical suppliers outside Russia, introducing contamination and quality risks separate from their intrinsic safety profiles. Third-party certificates of analysis from accredited laboratories are essential for any purchase. Neither peptide has established long-term human safety data beyond clinical trial durations (generally 14 to 30 days). Structuring use within cycling protocols and maintaining physician oversight are the minimum standards for responsible use.

WADA Status

Neither Selank nor Semax is explicitly named on the 2026 World Anti-Doping Agency Prohibited List. However, WADA's S0 category prohibits any pharmacological substance with no current approval by any major governmental regulatory health authority for human therapeutic use. Because neither is approved by the FDA, EMA, or other Western authorities — Selank and Semax are approved in Russia — they could fall under S0 classification. Athletes subject to anti-doping testing should consult their sport's anti-doping authority and treat both compounds as potentially prohibited.

Stacking: The Selank + Semax Protocol

The most established combination protocol in the nootropic community pairs Selank and Semax on the same day at alternating intervals. The rationale is mechanistically coherent: Selank's GABAergic anxiolysis creates a stable cognitive baseline while Semax's dopaminergic and BDNF-mediated enhancement builds upward from that baseline. The result is calm, focused alertness — neither the sedated plateau of anxiolytics alone nor the jittery stimulation of cognitive enhancers without anxiolytic support.

A typical combined protocol:

• Selank: 200–300 mcg intranasally upon waking
• Semax: 200–400 mcg intranasally at midday or early afternoon
• Course length: 14 to 21 days
• Break: 2 to 4 weeks before repeating

Some users administer both simultaneously in the morning, relying on the mechanistic separation to prevent adverse interaction. No formal combination trials exist, but the absence of documented adverse interactions across extensive community use provides some reassurance.

Dose adjustments when stacking are worth considering: because each compound contributes to BDNF upregulation, some practitioners reduce individual doses by 20 to 30% relative to monotherapy to avoid excessive neurotrophin signaling (though this concern remains theoretical rather than clinically documented).

Conclusion

Selank and Semax represent the most substantiated pair of nootropic peptides currently available: both are genuine pharmaceuticals in one of the world's major pharmaceutical markets, both have clinical trial data in humans, and both derive from one of the most productive peptide research programs of the 20th century.

The core insight is that they are not competitors. Selank does what Semax cannot — reduce anxiety without sedation, stabilize enkephalin systems, and modulate immune function. Semax does what Selank does not — proactively drive BDNF upregulation, sensitize dopaminergic neurons, and protect against ischemic neurological damage. Using them strategically, whether individually or in combination, is a question of matching mechanism to goal.

The honest caveat is that both compounds sit outside Western regulatory frameworks. The clinical evidence, while genuinely compelling by the standards of the peptide space, comes from Russian institutions and has not been replicated in large-scale Western trials. Anyone using Selank or Semax outside Russia is doing so outside the approved therapeutic framework, and the appropriate disposition is informed interest balanced with clear-eyed recognition of what remains unvalidated by Western standards.

For more on how these peptides fit into a broader longevity and cognitive protocol, see the individual peptide guides for Selank and Semax.